Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Account Payables (2016 - 2025)

IGC Pharma (IGC) has disclosed Change in Account Payables for 16 consecutive years, with -$303000.0 as the latest value for Q3 2025.

  • Quarterly Change in Account Payables fell 15050.0% to -$303000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$142000.0 through Sep 2025, down 164.55% year-over-year, with the annual reading at $106000.0 for FY2025, 56.38% down from the prior year.
  • Change in Account Payables for Q3 2025 was -$303000.0 at IGC Pharma, down from $51000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $142000.0 in Q2 2023, with the low at -$303000.0 in Q3 2025.
  • Average Change in Account Payables over 5 years is -$19473.7, with a median of $8000.0 recorded in 2022.
  • Peak annual rise in Change in Account Payables hit 2650.0% in 2025, while the deepest fall reached 15050.0% in 2025.
  • Over 5 years, Change in Account Payables stood at -$61000.0 in 2021, then skyrocketed by 113.11% to $8000.0 in 2022, then surged by 1125.0% to $98000.0 in 2023, then tumbled by 32.65% to $66000.0 in 2024, then tumbled by 559.09% to -$303000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$303000.0, $51000.0, and $44000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.